P
Pol Specenier
Researcher at University of Antwerp
Publications - 80
Citations - 3157
Pol Specenier is an academic researcher from University of Antwerp. The author has contributed to research in topics: Cetuximab & Head and neck cancer. The author has an hindex of 21, co-authored 77 publications receiving 2332 citations.
Papers
More filters
Journal Article
Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.
Carolien Boeckx,Lina Blockx,Ken Op de Beeck,Ridha Limame,Guy Van Camp,Marc Peeters,Jan B. Vermorken,Pol Specenier,An Wouters,Marc Baay,Filip Lardon +10 more
TL;DR: It is indicated that increased expression of the ligand HB-EGF could contribute to resistance towards cetuximab in cetUXimab resistant HNSCC cells.
Journal ArticleDOI
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial
Rachel Galot,Christophe Le Tourneau,Esma Saada-Bouzid,Amaury Daste,Caroline Even,Philip R. Debruyne,Stéphanie Henry,Sylvie Zanetta,Anemie Rutten,Lisa Licitra,Jean-Luc Canon,Marie Christine Kaminsky,Pol Specenier,Sylvie Rottey,Joël Guigay,Anthony Kong,Inge Tinhofer,Edith Borcoman,Lieve Dirix,Tiana Raveloarivahy,Catherine Fortpied,Maureen Vanlancker,Marie Morfouace,Anne Sophie Govaerts,Jean-Pascal Machiels +24 more
TL;DR: The UPSTREAM trial as discussed by the authors is a biomarker-driven umbrella trial studying targeted therapies and immunotherapies in patients with recurrent/metastatic (R/M) SCCHN progressing after platinum therapy.
Journal ArticleDOI
Ipilimumab in melanoma
TL;DR: The addition ipilimumab to nivolumab is associated with a higher response rate and a better PFS, particularly in patients with PD-L1 negative tumors, albeit at the cost of a steep increase in grade 3–4 adverse event rate.
Journal ArticleDOI
The role of taxanes and targeted therapies in locally advanced head and neck cancer
Pol Specenier,Jan B. Vermorken +1 more
TL;DR: Taxane-containing triplets are clearly superior as an induction regimen in locally advanced squamous cell carcinoma of the head and neck when compared with cisplatin/5 fluorouracil which has been the standard for two decades.
Journal ArticleDOI
Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?
Gwen Van Nuffelen,Leen Van den Steen,Olivier M. Vanderveken,Pol Specenier,Carl Van Laer,Diane Van Rompaey,Cindy Guns,Steven Mariën,Marc Peeters,Paul Van de Heyning,Jan Vanderwegen,Marc De Bodt,Marc De Bodt +12 more
TL;DR: This randomized controlled trial is the first to systematically investigate the effect of different exercise loads in tongue strengthening exercise protocols, with different degrees of exercise load, on tongue strength and swallowing.